Cargando…
Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study
Aim: To assess the efficacy of focal photocoagulation of capillary macroaneurysms (CMA) to reduce the burden of intravitreal injections (IVI) in patients with macular edema (ME). Materials and Methods: Retrospective multicenter study in patients with diabetic ME or ME secondary to retinal vein occlu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966640/ https://www.ncbi.nlm.nih.gov/pubmed/36839631 http://dx.doi.org/10.3390/pharmaceutics15020308 |
_version_ | 1784897067186913280 |
---|---|
author | Séjournet, Lucas Kodjikian, Laurent Elbany, Sandra Allignet, Benoit Agard, Emilie Chaperon, Mayeul Billant, Jérémy Denis, Philippe Mathis, Thibaud Burillon, Carole Dot, Corinne |
author_facet | Séjournet, Lucas Kodjikian, Laurent Elbany, Sandra Allignet, Benoit Agard, Emilie Chaperon, Mayeul Billant, Jérémy Denis, Philippe Mathis, Thibaud Burillon, Carole Dot, Corinne |
author_sort | Séjournet, Lucas |
collection | PubMed |
description | Aim: To assess the efficacy of focal photocoagulation of capillary macroaneurysms (CMA) to reduce the burden of intravitreal injections (IVI) in patients with macular edema (ME). Materials and Methods: Retrospective multicenter study in patients with diabetic ME or ME secondary to retinal vein occlusion (ME-RVO). CMA associated with ME were selectively photocoagulated. Patients were followed for one year after photocoagulation. Results: 93 eyes of 76 patients were included in this study. At 6 months after the laser (n = 93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 2.52 to 1.52 at 6 months, p < 0.001). The mean BCVA remained stable (0.32 and 0.31 logMAR at baseline and 6 months, p = 0.95). At 12 months (n = 81/93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 4.44 to 2.95 at 12 months, p < 0.001), while the mean BCVA remained stable (0.32 and 0.30 logMAR at baseline and 12 months, p = 0.16). Conclusion: Focal laser photocoagulation of CMA seems to be effective and safe for reducing the burden of IVI in patients with ME. Their screening during the follow-up should be considered closely. |
format | Online Article Text |
id | pubmed-9966640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99666402023-02-26 Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study Séjournet, Lucas Kodjikian, Laurent Elbany, Sandra Allignet, Benoit Agard, Emilie Chaperon, Mayeul Billant, Jérémy Denis, Philippe Mathis, Thibaud Burillon, Carole Dot, Corinne Pharmaceutics Article Aim: To assess the efficacy of focal photocoagulation of capillary macroaneurysms (CMA) to reduce the burden of intravitreal injections (IVI) in patients with macular edema (ME). Materials and Methods: Retrospective multicenter study in patients with diabetic ME or ME secondary to retinal vein occlusion (ME-RVO). CMA associated with ME were selectively photocoagulated. Patients were followed for one year after photocoagulation. Results: 93 eyes of 76 patients were included in this study. At 6 months after the laser (n = 93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 2.52 to 1.52 at 6 months, p < 0.001). The mean BCVA remained stable (0.32 and 0.31 logMAR at baseline and 6 months, p = 0.95). At 12 months (n = 81/93), there was a significant decrease in mean macular thickness (from 354 µm to 314 µm, p < 0.001) and in mean IVI number (from 4.44 to 2.95 at 12 months, p < 0.001), while the mean BCVA remained stable (0.32 and 0.30 logMAR at baseline and 12 months, p = 0.16). Conclusion: Focal laser photocoagulation of CMA seems to be effective and safe for reducing the burden of IVI in patients with ME. Their screening during the follow-up should be considered closely. MDPI 2023-01-17 /pmc/articles/PMC9966640/ /pubmed/36839631 http://dx.doi.org/10.3390/pharmaceutics15020308 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Séjournet, Lucas Kodjikian, Laurent Elbany, Sandra Allignet, Benoit Agard, Emilie Chaperon, Mayeul Billant, Jérémy Denis, Philippe Mathis, Thibaud Burillon, Carole Dot, Corinne Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study |
title | Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study |
title_full | Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study |
title_fullStr | Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study |
title_full_unstemmed | Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study |
title_short | Focal Photocoagulation as an Adjunctive Therapy to Reduce the Burden of Intravitreal Injections in Macula Edema Patients, the LyoMAC2 Study |
title_sort | focal photocoagulation as an adjunctive therapy to reduce the burden of intravitreal injections in macula edema patients, the lyomac2 study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966640/ https://www.ncbi.nlm.nih.gov/pubmed/36839631 http://dx.doi.org/10.3390/pharmaceutics15020308 |
work_keys_str_mv | AT sejournetlucas focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT kodjikianlaurent focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT elbanysandra focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT allignetbenoit focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT agardemilie focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT chaperonmayeul focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT billantjeremy focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT denisphilippe focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT mathisthibaud focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT burilloncarole focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study AT dotcorinne focalphotocoagulationasanadjunctivetherapytoreducetheburdenofintravitrealinjectionsinmaculaedemapatientsthelyomac2study |